abemaciclib
eli lilly
['bcsm', 'monarche,(-monarcher)', 'monarche']
in comparison the 3y idfs of the #monarche trial:
88.8 vs 83.4% ( 5.4%; hr 0.69) #asco23 #bcsm 
Breast Medical Oncologist @mdandersonnews - Lobular Specialist - Scientific advisor @LobularBCA.